



Publication number : **0 613 692 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(21) Application number : **94301513.1**

(51) Int. Cl.<sup>5</sup> : **A61L 15/28**

(22) Date of filing : **02.03.94**

(30) Priority : **03.03.93 GB 9304309**

(43) Date of publication of application :  
**07.09.94 Bulletin 94/36**

(84) Designated Contracting States :  
**AT CH DE DK ES GB IT LI PT SE**

(71) Applicant : **JOHNSON & JOHNSON MEDICAL,  
INC.  
2500 Arbrook Boulevard  
Arlington, Texas 76014 (US)**

(72) Inventor : **Hardy, Craig J.  
5 Brooklands Terrace  
Skipton, North Yorkshire BD23 (GB)**

(74) Representative : **Fisher, Adrian John et al  
CARPMAELS & RANSFORD  
43 Bloomsbury Square  
London WC1A 2RA (GB)**

(54) **Water soluble wound dressing materials.**

(57) The invention provides water soluble wound dressing materials comprising from 5% to 50% of an alginate ester of a C<sub>1</sub>-C<sub>6</sub> polyhydric alcohol; from 50% to 95% of a humectant consisting of one or more C<sub>1</sub>-C<sub>6</sub> monohydric or polyhydric alcohols; and from 0% to 30% of water, the percentages being calculated by weight based on the weight of the material when anhydrous. The preferred alginate ester is propylene glycol alginate (PGA). The materials dissolve in water at temperatures below 40°C. The materials are normally produced in the form of soft, conformable, wound-friendly films. The materials may also comprise medicaments or antiseptics.

**EP 0 613 692 A1**

The present invention relates to a water soluble material suitable for application to the surface of a wound as or in a wound dressing.

The use of biopolymers as the wound contacting layer of wound dressings is well known in the art. Biopolymers may be made absorbent, biocompatible and resorbable, thereby assisting wound healing. In addition, several biopolymers such as collagen, chitin, chitosan and alginates have been shown actively to assist wound healing by chemotaxis. Some biopolymers also exhibit a haemostatic effect.

Among the preferred biopolymers for wound healing applications are the alginates. This is on account of the abundance of alginates, their well-understood physicochemical properties and their proven chemotactic effect on wound healing. The alginates may be applied to the wound in a water-soluble form, for example by dusting sodium alginate powder onto the wound. Alternatively, the alginate may be applied as insoluble calcium alginate, or as an insoluble and water-swellaable mixture of sodium alginate and calcium alginate. The soluble or insoluble alginate may be in the form of fibres, a fleece, a gauze or a film. It may be attached to other elements of a wound dressing such as an absorbent layer, a semi-permeable or impermeable backing layer, and/or an adhesive-coated layer. Typical such alginate fleeces and wound dressings incorporating them are disclosed, for example, in GB-A-1379158, GB-A-906911, US-A-4793337, WO 90/01954, US-A-4393048, EP-A-0227955, EP-A-0099758, EP-A-0344913 and EP-A-0459378.

For many applications a continuous film of alginate is desirable as the wound contacting layer. Such a film presents a uniform contacting surface to the wound and helps to exclude bacteria from the wound. Continuous films are also easier to remove without disrupting the wound bed.

Alternatively, the film may be perforated or reticulated to allow passage through the film of heavy flows of exudate from the wound while remaining easily removable.

In order to be useful, the alginate film should preferably be strong, elastic, highly conformable, inexpensive, absorbent and sterilizable by gamma irradiation. Preferably, the alginate film should contain a high proportion of humectants such as glycerol so as to maintain a moist wound surface.

Hitherto, no alginate-containing film has provided the optimum combination of properties for use as a wound dressing. For example, anhydrous films of calcium and/or sodium alginate have been suggested for this application. However, the anhydrous films may incorporate only up to about 10% by weight of humectants, which is insufficient for effective moisturising of the wound surface. Moreover, the high alginate content of the anhydrous films makes them relatively expensive. The amount of humectant incorpo-

rated in the films may be increased by incorporating water as well, and this also reduces the cost of the film. However, incorporation of water weakens the films. Films containing water present storage problems because they dry out in air. Films containing substantial amounts of water cannot be sterilized by gamma-irradiation.

EP-A-0459378 (FIDIA S.p.A) discloses films containing between 1% and 7.5% by weight of one or more alkali metal alginates such as sodium alginate, from 0.1% to 5% of an alkali earth alginate such as calcium alginate, from 0.1% to 10% of a polyhydric alcohol and from 0.05% to 10% of a hydrophilic polymer such as hyaluronic acid, the balance of the composition being mainly water. The film is made by extruding a solution containing sodium alginate into a calcium chloride bath, where insoluble calcium alginate is formed. The resulting film cannot be sterilised by gamma-irradiation and must be stored under a glycerol/water solution to prevent it from drying out.

EP-A-0095892 (Nippon Oil Co. Ltd.) discloses perforated wound-covering films that comprise: 1.5-8% by weight of a polyvinyl alcohol (PVA), from 10-85% by weight of a polyhydric alcohol humectant and from 0.2-15% by weight of a water-soluble macromolecular substance other than PVA. The water-soluble macromolecular substance is typically a biopolymer or derivative thereof, or a synthetic polymer, provided that it forms a viscous aqueous solution. Preferred macromolecular substances are pullulan, xanthan gum, tragacanth gum, carboxymethylcellulose, polyacrylic acid, i-carrageenan,  $\lambda$ -carrageenan or propylene glycol alginate (PGA). These wound covering films are inexpensive, moisturising, strong, anhydrous and swellable but not soluble in cold or warm water. The main drawback of these films is that the inclusion of PVA even at low concentrations such as 1.5% results in a film that is stiff and rubbery and insufficiently conformable to make a satisfactory wound dressing. The film that contains both PGA and PVA can provide some of the advantageous wound healing properties of the alginate, but the presence of PVA and the rubbery texture of the film mean that the rate of release of PGA into the wound is very slow.

Accordingly, it is an object of the present invention to provide wound dressing materials that are especially suitable for casting into highly conformable wound covering films, and that provide for rapid release of alginate into the wound bed.

The present invention provides a water-soluble wound dressing material comprising, by weight based on the weight of the material when anhydrous: from 5% to 50% of an alginate ester of one or more C<sub>1</sub>-C<sub>6</sub> polyhydric alcohols; from 50% to 95% of a humectant consisting of one or more C<sub>1</sub>-C<sub>6</sub> monohydric or polyhydric alcohols; and from 0% to 30% of water.

The materials according to the present invention are water-soluble. That is to say, they will dissolve in

cold or warm water at temperatures below 40°C.

The preferred alginate ester is propylene glycol alginate (PGA). PGA is manufactured by reacting an alginate and propylene oxide at high temperatures. It is available, for example, from Protan Ltd. under the Registered Trade Mark PROTANAL. The viscosity and degree of esterification of the alginate ester are not critical to the materials of the present invention, but preferably the degree of esterification of the alginate is between 35% and 95%. That is to say, between 35% and 95% of the carboxylate groups of the alginate are esterified with the one or more C<sub>1</sub>-C<sub>6</sub> polyhydric alcohols. The remaining carboxylate groups are normally sodium carboxylate groups.

The esterification of the alginate with a polyhydric alcohol greatly increases the affinity of the alginate for humectants consisting of one or more C<sub>1</sub>-C<sub>6</sub> monohydric or polyhydric alcohols. Larger amounts of such humectants can be incorporated into wound dressing materials based on the alginate esters than can be incorporated into anhydrous sodium or calcium alginate materials. Preferably, the materials according to the present invention comprise from 65% to 90% by weight of the humectant. Polyhydric alcohols are the preferred humectants. Preferably, the humectant comprises propylene glycol or glycerol. Other preferred humectants are sorbitol and mannitol.

The high humectant content of the materials according to the present invention makes them especially suitable for use as or in moisturising wound dressings. Furthermore, the materials containing a high proportion of humectants are relatively inexpensive because the humectant is much less costly than alginate. The use of at least 5% by weight of the alginate ester allows surprisingly strong films to be made without the need to add any reinforcing polymer such as PVA. Preferably the materials according to the present invention contain at least 10% by weight, more preferably more than 15% but less than 25% by weight of the alginate ester.

The affinity of the alginate ester for the humectant means that the above high humectant content can be achieved without the need for a high water content in the wound dressing material. Preferably, the materials according to the present invention contain from 5% to 15% by weight of water and more preferably they contain less than 5% by weight of water. The low water content makes the materials sterilizable by gamma-irradiation and also avoids the problem of the materials drying out by evaporation when they are stored in air. The materials according to the present invention typically absorb moisture from the ambient air until they reach an equilibrium water content of 5%-15% by weight depending on the ambient humidity. Because of this variability in the water content of the films all of the weight percentages given for the components in the materials according to the

present invention are based on the weight of the material when anhydrous.

The materials according to the present invention optionally contain up to 5% by weight of dissolved salts. Preferably the dissolved salt content is 2% by weight or less of the composition. The dissolved salts preferably contain sodium chloride and may further comprise other salts in physiologically acceptable concentrations.

The materials according to the present invention preferably also comprise up to 2% by weight of a microbicide such as chlorhexidine or an antibiotic to provide protection against wound infection.

The materials according to the present invention preferably also comprise up to 25% by weight of one or more substances that are pharmacologically active to promote wound healing. These substances may comprise molecules such as cytokines and/or biopolymers such as collagen or chitin that have been shown to be effective at promoting wound healing.

The wound dressing materials according to the present invention may be prepared in any convenient physical form, such as a continuous or perforated film, a web, a foam or a fleece of woven or nonwoven fibres. Preferably the material is prepared as a continuous or perforated film.

The wound dressing materials according to the present invention may be prepared in straightforward fashion by mixing together the ingredients with an additional amount of water (up to 50% by weight) to form a gel, casting or extruding the gel in the desired shape and drying the gel at about 80°C to produce the desired wound dressing material. A further advantage of the wound dressing materials according to the present invention is that relatively little water needs to be evaporated during the manufacturing process in comparison with the manufacture of anhydrous sodium or calcium alginate wound dressings.

Specific embodiments of wound dressing materials according to the present invention will now be described further, by way of example.

#### Example 1

A continuous wound-covering film is prepared as follows. First, 4g of propylene glycol alginate (PGA) is dissolved in a mixture of 12.5g of propylene glycol and 12.5g of glycerol. The PGA is PROTANAL Ester PVH-A, available from Protan Ltd. The degree of esterification is 55-65% and the viscosity of a 1% aqueous solution of the PGA is 1400±200 mPaS.

The above solution is mixed with a solution of 0.45g of sodium chloride in water to form a gel. The gel is spread by a knife onto a casting roller in a layer approximately 2mm thick and dried in air at 80°C for 90 minutes. The water content of the film immediately after drying is less than 5% by weight, increasing to an equilibrium value of about 10% by weight on stand-

ing in the atmosphere.

### Example 2

A continuous wound-covering film is prepared as in Example 1, but with replacement of the 4g of PROTANAL Ester PVH-A by 6g of PROTANAL Ester CF. The latter is a PGA having a degree of esterification of 83% and a viscosity (1% aqueous solution) of  $20 \pm 5$  mPaS.

The films obtained in Examples 1 and 2 both show excellent strength, conformability and softness. The high level of humectant in the films makes them effective moisturising wound dressings. The films are very pleasant to handle and are stable in air. No leaching of the humectants is visible when the films are sterilized by gamma-irradiation. Little significant difference in properties is observed between the films of Examples 1 and 2.

The above examples are intended solely for the purpose of illustration. Many other wound dressing materials falling within the scope of the accompanying claims will be apparent to the skilled reader.

### Claims

1. A water-soluble wound dressing material comprising, by weight based on the weight of the material when anhydrous:  
from 5% to 50% of an alginate ester of one or more  $C_1$ - $C_8$  polyhydric alcohols;  
from 50% to 95% of a humectant consisting of one or more  $C_1$ - $C_8$  monohydric or polyhydric alcohols; and  
from 0% to 30% of water.
2. A water-soluble wound dressing material according to claim 1 wherein the alginate ester comprises propylene glycol alginate.
3. A water-soluble wound dressing material according to claim 1 or 2 wherein the degree of esterification of the alginate ester is from 35% to 95%.
4. A water-soluble wound dressing material according to claim 1, 2 or 3 wherein the humectant comprises glycerol or propylene glycol.
5. A water-soluble wound dressing material according to any preceding claim wherein the material comprises from 10% to 25% by weight based on the weight of the material when anhydrous of the alginate ester.
6. A water-soluble wound dressing material according to any preceding claim wherein the material comprises from 65% to 90% by weight based on

the weight of the material when anhydrous of the humectant.

7. A water-soluble wound dressing material according to any preceding claim wherein the material comprises from 5% to 15% by weight of water.
8. A water-soluble wound dressing material according to any preceding claim further comprising from 0% to 25% by weight based on the weight of the material when anhydrous of one or more substances that are pharmacologically active to promote wound healing.
9. A water-soluble wound dressing material according to claim 8 wherein the said one or more substances that are pharmacologically active to promote wound healing comprise a cytokine or a biopolymer other than an alginate.
10. A water-soluble wound dressing material according to any preceding claim further comprising from 0% to 2% by weight based on the weight of the material when anhydrous of an antimicrobial substance.
11. A water-soluble wound dressing material according to any preceding claim in the form of a continuous or perforated film.
12. A water-soluble wound dressing material substantially as hereinbefore described with reference to the examples.



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 94 30 1513

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CLS)
D,X	EP-A-0 095 892 (NIPPON OIL CO. LTD.) * page 14, line 17; claims; example 1 * ---	1,2,4,8,10	A61L15/28
D,X	US-A-4 393 048 (MASON A.D. ET AL.) * claims * ---	1,8,10	
D,X	EP-A-0 459 378 (FIDIA S.P.A.) * claims * ---	1,4	
P,X	EP-A-0 532 275 (JOHNSON & JOHNSON MEDICAL INC.) * the whole document * ---	1,4,8,10	
Y	EP-A-0 439 339 (SAKAI CHEMICAL INDUSTRY CO. LTD.) * page 3, line 51 - line 53; example 23 * ---	1-12	
P,Y	EP-A-0 568 368 (JOHNSON & JOHNSON MEDICAL INC.) * claims * ---	1-12	
A	US-A-4 369 929 (ERNEST J. SASMOR; KENNETH G. ROTHWELL.) * example 3 * -----	1	<div>TECHNICAL FIELDS SEARCHED (Int.CLS)</div> <div>A61L</div>
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 26 May 1994	Examiner ESPINOSA, M
<div>CATEGORY OF CITED DOCUMENTS</div> <div> X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document  T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons  &amp; : member of the same patent family, corresponding document </div>			

EPO FORM 1500 01.82 (P04C01)